3,149 reports of this reaction
1.5% of all TADALAFIL reports
#16 most reported adverse reaction
FLUID RETENTION is the #16 most commonly reported adverse reaction for TADALAFIL, manufactured by United Therapeutics Corporation. There are 3,149 FDA adverse event reports linking TADALAFIL to FLUID RETENTION. This represents approximately 1.5% of all 207,750 adverse event reports for this drug.
TADALAFIL has an overall safety score of 85 out of 100. Patients taking TADALAFIL who experience fluid retention should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FLUID RETENTION is a less commonly reported adverse event for TADALAFIL, but still significant enough to appear in the safety profile.
In addition to fluid retention, the following adverse reactions have been reported for TADALAFIL:
The following drugs have also been linked to fluid retention in FDA adverse event reports:
FLUID RETENTION has been reported as an adverse event in 3,149 FDA reports for TADALAFIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
FLUID RETENTION accounts for approximately 1.5% of all adverse event reports for TADALAFIL, making it a notable side effect.
If you experience fluid retention while taking TADALAFIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.